Institution
Renji Hospital
Healthcare•Shanghai, China•
About: Renji Hospital is a healthcare organization based out in Shanghai, China. It is known for research contribution in the topics: Medicine & Cancer. The organization has 1112 authors who have published 714 publications receiving 15442 citations. The organization is also known as: Rénjì Yīyuàn.
Topics: Medicine, Cancer, Population, Gene, Helicobacter pylori
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This review focuses on the ERK MAPK signal-transduction pathway, the consequences of its dysregulation in colorectal cancer, and its potential as an approach to cancer treatment.
Abstract: There are three major subfamilies of mitogen-activated protein kinases (MAPK): the extracellular-signal-regulated kinases (ERK MAPK); the c-jun N-terminal kinase or stress-activated protein kinases (JNK or SAPK); and MAPK14. The ERK MAPK pathway is one of the most important for cell proliferation. The MAPK pathways are located downstream of many growth-factor receptors, including that for epidermal growth factor. Overexpression and activation of this receptor are commonly detected in colorectal cancer, and several lines of evidence indicate that overexpression and activation of ERK MAPK play an important part in progression of this cancer. ERK MAPK could be a molecular target for treatment of the disorder. This review focuses on the ERK MAPK signal-transduction pathway, the consequences of its dysregulation in colorectal cancer, and its potential as an approach to cancer treatment. Future challenges for the assessment of these targeted agents in the clinic are also presented.
839 citations
••
TL;DR: Although enhancers can function in an orientation-independent manner in reporter assays, in the native chromosome context, the orientation of at least some enhancers carrying CBSs can determine both the architecture of topological chromatin domains and enhancer/promoter specificity.
821 citations
•
TL;DR: As a new kind of substrate of IIF, beta( 2)GP I transfectant can be used to detect anti-beta(2)GP-I antibodies and keep the immunofluorescent property of HEp-2 cells in IFANA test and can be use as substrate for routine IFANA detection.
Abstract: OBJECTIVE To establish an indirect immunofluorescent test so as to improve the sensitivity and specificity of examination of antibodies to beta(2)-glycoprotein METHODS Full-length beta(2)GP cDNA was obtained from human hepatocellular cancer cell line HepG2 by RT-PCR and cloned into the mammalian expression vector pEGFP-C1 The recombinant plasmid pEGFP-beta(2)GP was transfected into HEp-2 cells RT-PCR, immunoblotting (IBT), confocal fluorescence microscopy, and indirect immunofluorescent test (IIF) were used to confirm the expression, localization, and antigenicity of fusion protein of green fluorescent protein (GFP) Serum specimens from 19 patients suspected as with secondary antiphospholipid syndrome (APS), 1 patient diagnosed as with primary APS, and 10 normal persons were detected with IIF-IgG-beta(2)GP1, ELISA-IgG-ACL, and ELISA-IgG-beta(2)GP I simultaneously RESULTS (1) The HEp-beta(2)GP I cells thus obtained retained their ability of expression of beta(2)GP-I-GFP for more than ten generations This beta(2)GP-I-GFP showed the antigenicity of beta(2)GP-I with a characteristic feature (2) Seven of the 20 serum specimens from APS patients showed characteristic immunofluorescent pattern No serum specimen from normal persons showed immunofluorescent staining The comparison of results of the three methods showed that the concordance between IIF-IgG-beta(2)GP I and ELISA-IgG-beta(2)GP I was the most perfect (Kappa = 0886) (3) HEp-beta(2)GP I retained the immunofluorescent property of HEp-2 cell CONCLUSION As a new kind of substrate of IIF, beta(2)GP I transfectant can be used to detect anti-beta(2)GP-I antibodies Transfeted HEp-2 cells keep the immunofluorescent property of HEp-2 cells in IFANA test and can be used as substrate for routine IFANA detection
777 citations
••
TL;DR: Interleukin-6 antagonism has been shown to be a potential therapy for these disorders refractory to conventional drugs, and new strategies, such as combination of IL-6 blockade with inhibition of other signaling pathways, may further improve IL- 6-targeted immunotherapy of human diseases.
434 citations
••
Shanghai Jiao Tong University1, Zhejiang University2, Huazhong University of Science and Technology3, Fujian Medical University4, Shanxi Medical University5, Bengbu Medical College6, Second Military Medical University7, Capital Medical University8, Guangxi Medical University9, Renji Hospital10, Fudan University11, Tongji University12, Dalian Medical University13
TL;DR: This work identified somatic gene mutations in 25 people with NKTCL by whole-exome sequencing and confirmed them in an extended validation group of 80 people by targeted sequencing, contributing to the understanding of the disease mechanism ofNKTCL.
Abstract: Zhu Chen, Sai-Juan Chen, Wei-Li Zhao and colleagues identify recurrent loss-of-function mutations in the RNA helicase gene DDX3X in 20% of subjects with natural killer/T-cell lymphoma (NKTCL) in their study. The results suggest that DDX3X acts as a tumor suppressor and that its inactivation leads to poor clinical outcome.
284 citations
Authors
Showing all 1170 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jaap Stoker | 66 | 404 | 15532 |
Nan Shen | 56 | 238 | 13592 |
Carola G. Vinuesa | 54 | 128 | 17433 |
Jing-Yuan Fang | 54 | 289 | 10826 |
Honglan Li | 53 | 199 | 8285 |
Matthew C. Cook | 43 | 119 | 9708 |
Guido N. J. Tytgat | 40 | 102 | 6175 |
Jianrong Xu | 37 | 226 | 4915 |
Eric J.H. Meuleman | 37 | 126 | 6184 |
Xiong Ma | 35 | 127 | 3587 |
Gang Huang | 34 | 116 | 3122 |
Jinke Cheng | 33 | 97 | 4120 |
Jie Xu | 32 | 83 | 3150 |
Steven R. Lindheim | 30 | 186 | 3594 |
Qiang Wu | 29 | 75 | 4203 |